Polyethylene Oxide
A China-based PEO supplier · direct drop-in replacement for the Dow WSR / Sumitomo series
A drop-in alternative to the Dow WSR and Sumitomo series — no reformulation required
Product Profile
- CAS No.
- 25322-68-3
- Alias
- Macrogols, high-molecular-mass (high-molecular-weight polyethylene glycol)
- Formula / molecular weight
- Molecular weight 100,000 – 7,000,000 (10 grade brackets)
- Grade
- Pharma excipient grade (Excipact GMP certified)
- Function
- Sustained-release excipient — hydrophilic gel matrix and osmotic-pump push agent
- Appearance
- White to off-white, free-flowing powder
- Solubility
- Freely soluble in water
- Compendial standards
- USP-NF / EP / ChP
- Therapeutic area
- Oral sustained / controlled-release formulations
- Packaging / form
- Packaged to customer requirement (powder; moisture-protected)
- Delivery
- MOQ and lead time negotiable (ton-scale supply supported)
Key Application Scenarios
Hydrophilic gel-matrix extended-release tablets
Rapidly hydrates in contact with water to form a gel barrier that controls the drug-release rate — the most common oral extended-release technology.
Push–pull osmotic pump (PPOP) push layer
Acts as a swelling agent in the push layer; it absorbs water and expands to drive the drug layer, achieving zero-order release independent of pH and food intake.
Drug-layer suspending agent
Within the drug layer of a push–pull osmotic pump it keeps the drug uniformly dispersed, preventing sedimentation and phase separation.
Grade cross-reference table (10 molecular-weight brackets)
| Our grade | Mol. weight | Viscosity / key metric | Benchmark / standard | Note |
|---|---|---|---|---|
| PEO-10 | 100,000 | 12 ~ 50 mPa·s (30 g / 570+125 ml) | Dow WSR N-10 / Sumitomo PEO-1 | |
| PEO-20 | 200,000 | 65 ~ 115 mPa·s (30 g / 570+125 ml) | Dow WSR N-80 | |
| PEO-40 | 400,000 | 2250 ~ 4500 mPa·s (30 g / 570+125 ml) | — | |
| PEO-60 | 600,000 | 4500 ~ 8800 mPa·s (30 g / 570+125 ml) | — | |
| PEO-90 | 900,000 | 8800 ~ 17,600 mPa·s (30 g / 570+125 ml) | Dow WSR-1105 | |
| PEO-100 | 1,000,000 | 400 ~ 800 mPa·s (12 g / 588+125 ml) | Dow WSR N-12K / Sumitomo PEO-3 | |
| PEO-200 | 2,000,000 | 2000 ~ 4000 mPa·s (12 g / 588+125 ml) | Dow WSR N-60K / Sumitomo PEO-8NF | |
| PEO-400 | 4,000,000 | 1650 ~ 5500 mPa·s (6 g / 594+125 ml) | Dow WSR-301 / Sumitomo PEO-15 | |
| PEO-500 | 5,000,000 | 5500 ~ 7500 mPa·s (6 g / 594+125 ml) | Dow WSR Coagulant / Sumitomo PEO-18 | |
| PEO-700 | 7,000,000 | 7500 ~ 10,000 mPa·s (6 g / 594+125 ml) | Dow WSR-303 / Sumitomo PEO-20NF |
Viscosity test conditions vary by molecular-weight bracket (sample and solvent volumes are noted in parentheses); benchmark grades are for reference only — technical support is available for grade selection.
Data File Pack
Zero Registration Risk · Audits Fully Open
Excipient-specific GMP certification issued by SGS
China DMF filing completed; supports customer formulation registration
On-site customer audits welcome (Site Audit)
Full regulatory documentation support provided
Key Selling Points
- ✓Complies with current USP-NF / EP / ChP
- ✓CoA and inter-batch consistency data provided
- ✓Direct drop-in replacement — no reformulation required
- ✓Equivalent to the Dow WSR and Sumitomo series
Validated downstream formulations
| Product / formulation | INN / company | Dosage form |
|---|---|---|
| Metformin HCl extended-release tablet | Metformin HCl ER · Verified formulation case | Matrix ER tablet: drug 50% + PEO 30% + MCC 19% + lubricant 1%, direct compression |
The product names above are for illustrating this excipient's actual use scenarios and volume scale only; trademarks belong to their respective owners and imply no affiliation or endorsement.
Compiled from Polyethylene Oxide (PEO) product documentation (Sep 2026 edition); we recommend re-verifying the molecular-weight–viscosity benchmark relationship against the source before release.
Document version: 2026-09 · CoA and inter-batch consistency data provided · on-site audits supported